Floxuridine
Top View
- Use of Anti-Emetics in Adults Receiving Anti-Cancer Drug Therapy
- Table III 2021 Medicare National Drug Fee Schedule
- (12) Patent Application Publication (10) Pub. No.: US 2011/0160159 A1 Ryan (43) Pub
- 2012 NIOSH List of Antineoplastic and Other Hazardous Drugs
- Perioperative Medication Management - Adult/Pediatric - Inpatient/Ambulatory Clinical Practice Guideline
- Pemetrexed and Gemcitabine As Combination Therapy for the Treatment of Group3 Medulloblastoma
- Topotecan and Doxorubicin Combination to Treat Recurrent
- Floxuridine ASHP INJECTABLE DRUG INFORMATION
- Principles of Antineoplastic Therapy
- Characterization of Uracil Dna Glycosylase As a Therapeutic Target for Sensitization of Floxuridine in Cancer with P53 Mutation Or Deficiency
- Safe Handling of Hazardous Chemotherapy Drugs in Limited-Resource Settings
- How to Order Chemotherapy at Shands at the University of Florida - Inpatient
- Pharmacokinetics of Intraarterial Mitomycin C in Humans1
- Emetogenic Potential of Antineoplastic Agents
- Pharmacist Involvement in the Management of Adverse Effects
- Adult Antiemetic Management of Chemotherapy-Induced Nausea
- Supplementary Table 1. Summary of FDA-Approved Anticancer Cytotoxic Drugs at May 2019
- Antitumor Activity and Murine Pharmacokinetics of Parenteral Acronycine1